Topics

Finch Therapeutics Group Company Profile

10:01 EST 27th January 2020 | BioPortfolio

Finch Therapeutics, a mission-driven microbiome engineering company, is developing novel microbial therapies to serve patients with serious and unmet medical needs. Founded by data scientists, clinicians, and microbiologists from MIT and OpenBiome, Finch uses machine- learning algorithms informed by high-throughput molecular data to reverse engineer successful clinical experience with fecal transplantation. Rather than relying on in-vitro screening of a library of microbes, Finch uses this human-first discovery approach to identify strains that drive clinical outcomes and to develop therapies that deliver these microbial communities to patients. FIN-524, a collection of microbes grown in pure culture to treat IBD, is Finch’s first product candidate based on a Rationally-Selected Microbiota™.


News Articles [1298 Associated News Articles listed on BioPortfolio]

GILEAD AND GALAPAGOS ANNOUNCE EFFICACY AND SAFETY RESULTS OF FILGOTINIB THROUGH 52 WEEKS IN FINCH 1 AND FINCH 3 STUDIES IN RHEUMATOID ARTHRITIS

  Foster City, Calif. and Mechelen, Belgium; October 11, 2019, 0.00 CET; – Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that Week...

Gilead, Galapagos announce 52-week results of filgotinib in FINCH 1, FINCH 3 studies in rheumatoid arthritis

“We are encouraged by the durability of both the efficacy and safety profiles of filgotinib seen in these studies,” said John Sundy, MD, PhD, Senior Vice President, Inflammation The post Gilead, ...

Galapagos NV: GILEAD AND GALAPAGOS ANNOUNCE EFFICACY AND SAFETY RESULTS OF FILGOTINIB THROUGH 52 WEEKS IN FINCH 1 AND FINCH 3 STUDIES IN RHEUMATOID ARTHRITIS

Foster City, Calif. and Mechelen, Belgium; October 11, 2019, 0.00 CET; - Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that Week 52 data from the r...

Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib Through 52 Weeks in Late-Stage Rheumatoid Arthritis Studies

FOSTER CITY, Calif. & MECHELEN, Belgium–(BUSINESS WIRE)–Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that Week 52 data from the r...

Gilead Plans NDA for Rheumatoid Arthritis Drug Filgotinib

Based on positive data from its FINCH program, Gilead aims to seek regulatory approval for its Jak inhibitor.

Executives On The Move: Menarini Group Chooses Next CEO, Crescendo Decides On A CBO And Scholar Rock Adds Head, Medical Research

At Italian Biopharma Menarini Group a former Merck KGaA head of new business is now CEO. Oncology therapeutics firm Crescendo...   

Nascent digital therapeutics group lays out best practices, ethics

The two-year-old group is looking to differentiate higher-risk products that claim to treat disease from more general digital health and wellness apps.

Galapagos NV: NEW DATA ON FILGOTINIB IN RHEUMATOID ARTHRITIS (RA) DEMONSTRATE DURABLE EFFICACY AND SAFETY PROFILE

-- Pooled Analysis from the FINCH RA Clinical Program with Investigational Filgotinib Reinforces Favorable Safety and Tolerability Profile Alone and in Combination with Methotrexate (MTX) or Conve...

Drugs and Medications [27 Associated Drugs and Medications listed on BioPortfolio]

Kynamro [kastle therapeutics, llc]

NA

Olopatadine hydrochloride [somerset therapeutics, llc]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

Oxygen [breathe easy therapeutics, inc]

NA

Diclofenac sodium delayed release [cambridge therapeutics technologies, llc]

Diclofenac Sodium

Olopatadine hydrochloride [a-s medication solutions]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

PubMed Articles [2097 Associated PubMed Articles listed on BioPortfolio]

Digital Therapeutics: Emerging New Therapy for Neurologic Deficits after Stroke.

Digital therapeutics is an evidence-based intervention using high-quality software, with the sole purpose of treatment. As many healthcare systems are encountering high demands of quality outcomes, th...

Use of Topical 0.01% Atropine for Controlling Near Work-Induced Transient Myopia: A Randomized, Double-Blinded, Placebo-Controlled Study.

To investigate the efficacy and safety of topical low-concentration (0.01%) atropine for controlling near work-induced transient myopia (NITM) in a young Chinese population. This was a randomized, do...

Comparison of Efficacy of Intravitreal Ranibizumab and Aflibercept in Eyes with Myopic Choroidal Neovascularization: 24-Month Follow-Up.

To compare the 24-month efficacy of intravitreal ranibizumab and aflibercept in treatment-naive patients with myopic choroidal neovascularization (CNV). Ninety-six naive patients (97 eyes) with myopi...

Medical therapeutics: mortality effects, uncertainty, and informed consent.

Many drugs used in medical therapeutics are able to save human lives. Unfortunately, many such drugs have also led to the death of patients. This fact raises important issues discussed in light of a n...

Effect of Topical Corticosteroids on Early Postoperative Intraocular Pressure Following Combined Cataract and Trabecular Microbypass Surgery.

To evaluate the early postoperative outcomes of trabecular micro-bypass stents and concomitant cataract surgery (TMS-CS) with and without postoperative corticosteroid therapy. Prospective, interventi...

Clinical Trials [5287 Associated Clinical Trials listed on BioPortfolio]

Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy

The purpose of the study is to assess long-term side effects from subjects who receive a Fate Therapeutics genetically modified NK cell product. Subjects who previously took part in a Fate...

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

Feasibility Study of Microbial Ecosystem Therapeutics (MET-4) to Evaluate Effects of Fecal Microbiome in Patients on ImmunOtherapy

This study is designed to assess the safety, tolerability and engraftment (cumulative relative abundance) of MET-4 strains when given in combination with immune checkpoint inhibitors (ICIs...

Companies [3151 Associated Companies listed on BioPortfolio]

Xenova Group PLC

Xenova Group plc is an emerging pharmaceutical group, specialising in the development of new small molecule drugs. The company’s strategy is to develop commercially attractive new drugs, primarily i...

Lava Therapeutics

Lava Therapeutics’ proprietary platform is focused on developing next generation γδ T cell engaging bispecific antibodies to treat cancer. Our first-in-class immuno-onc...

Cambrooke Therapeutics Inc.

Founded in 2000, Cambrooke Therapeutics, a proud member of The Ajinomoto Group, is a Massachusetts-based therapeutic nutrition company and global provider of medical nutrition pro...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Akebia Therapeutics, Inc. and The Vifor Pharma Group

More Information about "Finch Therapeutics Group" on BioPortfolio

We have published hundreds of Finch Therapeutics Group news stories on BioPortfolio along with dozens of Finch Therapeutics Group Clinical Trials and PubMed Articles about Finch Therapeutics Group for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Finch Therapeutics Group Companies in our database. You can also find out about relevant Finch Therapeutics Group Drugs and Medications on this site too.

Quick Search

Relevant Topic

Transplantation
Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...


Corporate Database Quicklinks



Searches Linking to this Company Record